BlackRock’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-431,406
| Closed | -$1.15M | – | 5433 |
|
|
2024
Q1 | $1.15M | Sell |
431,406
-155,282
| -26% | -$384K | ﹤0.01% | 4165 |
|
|
2023
Q4 | $1.39M | Sell |
586,688
-154,662
| -21% | -$274K | ﹤0.01% | 4157 |
|
|
2023
Q3 | $1.04M | Buy |
741,350
+18,348
| +3% | +$44.1K | ﹤0.01% | 4232 |
|
|
2023
Q2 | $2.19M | Sell |
723,002
-1,554,107
| -68% | -$5.99M | ﹤0.01% | 4017 |
|
|
2023
Q1 | $14.2M | Sell |
2,277,109
-58,709
| -3% | -$358K | ﹤0.01% | 3139 |
|
|
2022
Q4 | $14.2M | Buy |
2,335,818
+59,002
| +3% | +$481K | ﹤0.01% | 3208 |
|
|
2022
Q3 | $27.2M | Sell |
2,276,816
-22,728
| -1% | -$297K | ﹤0.01% | 2859 |
|
|
2022
Q2 | $29M | Buy |
2,299,544
+244,320
| +12% | +$2.27M | ﹤0.01% | 2873 |
|
|
2022
Q1 | $23.1M | Buy |
2,055,224
+8,189
| +0.4% | +$90.1K | ﹤0.01% | 3084 |
|
|
2021
Q4 | $36.3M | Buy |
2,047,035
+172,674
| +9% | +$3.64M | ﹤0.01% | 2892 |
|
|
2021
Q3 | $43.1M | Buy |
1,874,361
+600,832
| +47% | +$13.1M | ﹤0.01% | 2763 |
|
|
2021
Q2 | $29.6M | Buy |
1,273,529
+63,331
| +5% | +$1.61M | ﹤0.01% | 3063 |
|
|
2021
Q1 | $37.7M | Buy |
1,210,198
+900,654
| +291% | +$31.4M | ﹤0.01% | 2807 |
|
|
2020
Q4 | $12.3M | Buy |
+309,544
| New | +$12.4M | ﹤0.01% | 3265 |
|
BlackRock's KNTE Position: Q2 2024 in Review
BlackRock sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 431,406 shares — an estimated $1.15M sold.
BlackRock first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $43.1M in Q3 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- BlackRock reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 431,406 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $1.15M.
- BlackRock first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
- BlackRock's Kinnate Biopharma Inc. Common Stock position peaked at $43.1M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.